NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA

NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc.

NTHI

0.00

— Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047)

— Median overall survival of 26.09 months; 86.7% of patients alive at six months

— Five of 24 patients remain on treatment, with one partial response ongoing beyond 114 days

— No major toxicities reported across the cohort; adverse events predominantly low-grade

— Company to host investor conference call and webcast today at 8:30 a.m. Eastern Time

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.